Why Is ULTRAGENYX PHARMACEU (RARE) Stock Moving Today?

Why RARE stock is up today

Ultragenyx Pharmaceutical (RARE) rose 5.05% to $15.19 in morning trading on October 7, 2026, following the company’s announcement of a $210 million deal to sell an FDA priority review voucher. The move reflects investor interest in the monetization of a non-core asset and signals the company’s ability to generate near-term liquidity. The stock opened lower but reversed sharply to post a new session high shortly after 10:30 AM ET.

What Happened

Ultragenyx announced on October 6, 2026, that it had entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher tied to its recent Genglycos approval. The voucher allows the holder to expedite the FDA review of a future drug application. The $210 million sale is expected to provide the company with immediate cash flow, which may be used to support ongoing operations or future development programs. The transaction was disclosed in a Form 8-K filed with the SEC on October 7, 2026.

Retail traders and institutional observers have highlighted the transaction as a significant development for a company with a market cap of $1.4 billion and a history of unprofitability. The stock’s performance was also supported by recent analyst activity, including raised price targets from Evercore ISI Group, Barclays, and Morgan Stanley.

What The Data Shows

The stock opened at $14.31, a 1.0% gap down from the prior close, but quickly reversed to reach a high of $15.21. Trading volume stood at 0.9 million shares by the close of the morning session, representing 0.2 times the 3-month daily average. The stock has traded in a 52-week range of $12.73 to $39.89, with today’s move pushing it closer to the upper end of that range. Over the last 8 sessions, the stock has risen 1.4% from $14.26 to $14.46. The company reported a TTM revenue increase of 17.5% but remains unprofitable with a net margin of -81.7%.

What To Watch

The stock is set to continue its session with a focus on how the market digests the cash inflow from the voucher sale. Investors may also monitor the company’s ability to execute on its broader pipeline, including its gene therapy for MPS IIIA, which recently cleared EMA validation.

Why is RARE stock moving today?

ULTRAGENYX PHARMACEU (RARE) is drawing unusual attention today. Our newswire has captured 2 stories on RARE across 2 sources in the last 36 hours, with AI sentiment reading mixed (avg 50/100). The most recent driver: "Ultragenyx to Host Conference Call for Third Quarter 2026 Financial Results and Corporate Update" (GlobeNewswire).

Is RARE a buy right now?

Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of RARE coverage reads 50/100 over 2 stories; treat it as a research signal and do your own diligence.

How fast does this page update?

The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.